Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Olaf Zent

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
International Journal of Medical Microbiology : IJMM|March 15, 2006
Response to tick-borne encephalitis (TBE) booster vaccination after prolonged time intervals to primary immunization with the rapid scheduleInes Schöndorf, Christian Schönfeld, Uwe Nicolay, et al.
International Journal of Medical Microbiology : IJMM|May 19, 2004
TBE booster immunization in adults--first experience with a new tick-borne encephalitis (TBE) vaccine, free of protein-derived stabilizerOlaf Zent, Tino F Schwarz, Annelie Plentz, et al.
Vaccine|December 17, 2008
Long-term persistence of tick-borne encephalitis antibodies in adults 5 years after booster vaccination with Encepur AdultsAnnelie Plentz, Wolfgang Jilg, Tino F Schwarz, et al.
Human Vaccines|February 14, 2007
Tick-born encephalitis (TBE) vaccination in children: advantage of the rapid immunization schedule (i.e., days 0, 7, 21)Ines Schoendorf, Gabor Ternak, György Oroszlàn, et al.
International Journal of Medical Microbiology : IJMM|March 10, 2006
Persistence of antibodies after vaccination against tick-borne encephalitisPamela Rendi-Wagner, Olaf Zent, Wolfgang Jilg, et al.
Expert Review of Vaccines|March 18, 2025
Pregnancy outcomes following unintentional exposure to TAK-003, a live-attenuated tetravalent dengue vaccineMartina Rauscher, Zeb Youard, Alice Faccin, et al.
Vaccine|October 31, 2003
Kinetics of the immune response after primary and booster immunization against tick-borne encephalitis (TBE) in adults using the rapid immunization scheduleOlaf Zent, Wolfgang Jilg, Annelie Plentz, et al.
Vaccine|November 9, 2004
TBE booster immunization according to the rapid immunization schedule: are 3-year booster intervals really necessary?Olaf Zent, Annelie Plentz, Tino F Schwarz, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 4, 2021
Three-year Efficacy and Safety of Takeda's Dengue Vaccine Candidate (TAK-003)Luis Rivera, Shibadas Biswal, Xavier Sáez-Llorens, et al.
The Lancet. Global Health|January 20, 2024
Long-term efficacy and safety of a tetravalent dengue vaccine (TAK-003): 4·5-year results from a phase 3, randomised, double-blind, placebo-controlled trialVianney Tricou, Delia Yu, Humberto Reynales, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
International Journal of Medical Microbiology : IJMM|March 15, 2006
Response to tick-borne encephalitis (TBE) booster vaccination after prolonged time intervals to primary immunization with the rapid scheduleInes Schöndorf, Christian Schönfeld, Uwe Nicolay, et al.
International Journal of Medical Microbiology : IJMM|May 19, 2004
TBE booster immunization in adults--first experience with a new tick-borne encephalitis (TBE) vaccine, free of protein-derived stabilizerOlaf Zent, Tino F Schwarz, Annelie Plentz, et al.
Vaccine|December 17, 2008
Long-term persistence of tick-borne encephalitis antibodies in adults 5 years after booster vaccination with Encepur AdultsAnnelie Plentz, Wolfgang Jilg, Tino F Schwarz, et al.
Human Vaccines|February 14, 2007
Tick-born encephalitis (TBE) vaccination in children: advantage of the rapid immunization schedule (i.e., days 0, 7, 21)Ines Schoendorf, Gabor Ternak, György Oroszlàn, et al.
International Journal of Medical Microbiology : IJMM|March 10, 2006
Persistence of antibodies after vaccination against tick-borne encephalitisPamela Rendi-Wagner, Olaf Zent, Wolfgang Jilg, et al.
Expert Review of Vaccines|March 18, 2025
Pregnancy outcomes following unintentional exposure to TAK-003, a live-attenuated tetravalent dengue vaccineMartina Rauscher, Zeb Youard, Alice Faccin, et al.
Vaccine|October 31, 2003
Kinetics of the immune response after primary and booster immunization against tick-borne encephalitis (TBE) in adults using the rapid immunization scheduleOlaf Zent, Wolfgang Jilg, Annelie Plentz, et al.
Vaccine|November 9, 2004
TBE booster immunization according to the rapid immunization schedule: are 3-year booster intervals really necessary?Olaf Zent, Annelie Plentz, Tino F Schwarz, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 4, 2021
Three-year Efficacy and Safety of Takeda's Dengue Vaccine Candidate (TAK-003)Luis Rivera, Shibadas Biswal, Xavier Sáez-Llorens, et al.
The Lancet. Global Health|January 20, 2024
Long-term efficacy and safety of a tetravalent dengue vaccine (TAK-003): 4·5-year results from a phase 3, randomised, double-blind, placebo-controlled trialVianney Tricou, Delia Yu, Humberto Reynales, et al.
Pageof 2